Hesperidin

Best-in-class: Hesperidin

A citrus flavonoid that strengthens blood vessels and supports circulation, blood pressure and venous health (varicose veins, hemorrhoids).

How Hesperidin actually works

A citrus flavonoid that improves endothelial function and reduces inflammatory markers, and — with diosmin — increases venous tone and reduces capillary permeability. It is metabolized by gut bacteria into hesperetin before absorption, which means microbiome composition genuinely affects how much any individual gets from it.

Where to get Hesperidin

The evidence for Hesperidin

Graded by what exists behind each claim.

✅ Clinically validated

• RCTs support improved endothelial function, blood pressure and venous/capillary integrity.
• Reduces vascular inflammation markers.

📊 Correlative data

• Citrus-flavonoid intake tracks with better vascular health.

🧪 Theoretical / extrapolated benefits

• Predicted to improve microvascular function through the same leukocyte-adhesion and capillary-permeability route as diosmin, which is why the two are almost always sold together — the combination is the studied unit, and hesperidin alone is a weaker proposition than the pairing.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Hesperidin actually does

The molecule sold as hesperidin is hesperetin-7-O-rutinoside, and the rutinoside is the entire story. Rutinose is rhamnose linked to glucose, and the human small intestine has no enzyme that removes rhamnose. Lactase-phloridzin hydrolase and cytosolic beta-glucosidase — the two enzymes that let a plain glucoside like quercetin-4'-glucoside be absorbed in the jejunum within an hour — cannot touch it. So hesperidin travels the length of the small intestine intact, reaches the colon, and waits for a bacterial alpha-L-rhamnosidase to cut the sugar off before the aglycone hesperetin can be absorbed at all Scalbert 2002Manach 2005. Everything odd about this supplement follows from that one enzymatic fact.

What that does to exposure. Absorption is displaced to the colon, so time to peak plasma concentration runs to five to seven hours rather than one, and the size of the peak depends on somebody else's enzyme — the rhamnosidase activity of an individual's gut flora, which varies several-fold between people Scalbert 2002Manach 2005. And what finally circulates is not hesperetin. It is hesperetin-7-O-glucuronide and hesperetin-3'-O-glucuronide plus sulfates, conjugated at the enterocyte and again in the liver Manach 2005. The free aglycone is essentially undetectable in plasma at dietary doses.

The vascular mechanism, named at the level it is argued. Three things are claimed for citrus flavanones at the vessel: nitric oxide availability, leukocyte–endothelium adhesion, and capillary permeability. The adhesion arm is the specific one — the pathophysiology of chronic venous disease runs through leukocyte rolling and trapping in the microcirculation via the selectins and ICAM-1/VCAM-1, with the trapped leukocytes releasing proteases that degrade the capillary basement membrane and produce the leak, the edema and eventually the ulcer Allaert 2016. A flavonoid that reduces adhesion-molecule expression interrupts that cascade at its start, which is a very different claim from “strengthens blood vessels”.

The venous-tone arm belongs to the other flavonoid in the bottle. The tone effect attributed to this class is prolongation of noradrenaline's action on the vein wall — classically explained by inhibition of its degradation by catechol-O-methyltransferase, so the transmitter persists longer in the adventitial cleft and the vein stays constricted. That mechanism is attached to diosmin and to the micronized diosmin–hesperidin fraction, not to hesperidin on its own Kakkos 2018. It is the reason the two are sold together, and the reason a hesperidin-only capsule is a weaker proposition than the pairing.

Cell, rodent, human — and where it stops

In cells. Endothelial monolayers exposed to hesperetin or its conjugates, reading eNOS phosphorylation, NF-kappaB-driven adhesion molecules and monolayer permeability. Typical culture concentrations sit at 10–50 micromolar of aglycone.

In rodents. Hesperidin by gavage in hypertensive and ischemia models, weeks of dosing, at 50–200 mg/kg. A 100 mg/kg rat dose is roughly 16 mg/kg human-equivalent by body-surface scaling, which is about 1.1 g for a 70 kg adult — more than twice the 500 mg on a typical label.

In people, twice, and the two trials disagree in a way that teaches something. Twenty-four healthy overweight men aged 50–65 took 500 mL of orange juice, a hesperidin supplement delivering the same 320 mg of hesperidin, or a control drink for four weeks each in randomized crossover: diastolic blood pressure was lower (P = 0.02) and postprandial microvascular reactivity improved (P < 0.05) Morand 2011. Then sixteen men aged 51–69 took a single dose of the same 320 mg of hesperidin, and eight flavanone and fifteen phenolic metabolites rose sharply in plasma (P < 0.0001) while not one cardiovascular risk biomarker moved Schar 2015.

That pair is the most useful thing on this page. The metabolites unquestionably arrive — the second trial proves it with twenty-three of them measured Schar 2015. Arriving is not the same as acting acutely. Whatever hesperidin does to a blood vessel, it takes four weeks and not four hours Morand 2011, which points at something transcriptional or structural rather than an acute vasodilator effect — and which means anyone judging this supplement inside a fortnight is judging it on the wrong timescale.

The venous evidence is not hesperidin's evidence. The clinical weight in this category sits with micronized purified flavonoid fraction: seven double-blind placebo-controlled trials, 1,692 patients with chronic venous disease, with leg pain (RR 0.53, NNT 4.2), heaviness (RR 0.35, NNT 2.0) and swelling (RR 0.39, NNT 3.1) all reduced and ankle circumference down (SMD −0.59) Kakkos 2018. Those numbers are good — an NNT of 2 for heaviness is better than most drugs manage — and they belong to a fraction that is 90% diosmin. Hesperidin is the 10%.

Hesperidin — which form, and does it matter

Micronized purified flavonoid fraction is a manufacturing specification, and every part of the name is load-bearing. MPFF is 90% diosmin and 10% flavonoids expressed as hesperidin, milled to particles under about 2 micrometers. The micronization exists because these flavonoids are barely soluble; smaller particles dissolve faster and are absorbed more completely. Plain non-micronized diosmin at the same milligram dose is not the same product, and the trials behind the NNTs above were run on the micronized fraction Kakkos 2018.

Hesperidin methyl chalcone is a different molecule again. The venotonic combination that carries the largest patient numbers outside MPFF pairs Ruscus aculeatus extract with hesperidin methyl chalcone and ascorbic acid Allaert 2016. Methyl chalcone is a synthetic, water-soluble, ring-opened derivative — chemically a chalcone rather than a flavanone. It is not hesperidin, it is not interchangeable with hesperidin, and a shopper reading “hesperidin” on both labels has been given the same word for two different compounds.

Enzymatically modified and 2S-enriched hesperidins exist because of the rhamnose problem. Glucosyl-hesperidin and micronized hesperidin preparations are engineered to bypass or accelerate the colonic deglycosylation step, and they change the plasma curve rather than the dose. If a product advertises improved solubility or absorption, that is the claim it is making — and it means the milligrams on its label are not comparable with the 320 mg used in the human trials Morand 2011Schar 2015.

What this means for the shelf. The site's own card gives 500 mg daily, often with diosmin. That is the honest recommendation, and the reason is now explicit: the trial evidence for symptoms belongs to the pairing Kakkos 2018, and the trial evidence for endothelial function belongs to 320 mg of plain hesperidin taken for four weeks Morand 2011. Those are two different products bought for two different reasons, and a single 500 mg hesperidin capsule cleanly serves only the second.

What would have to be true, and how you would know it was not

1. Diastolic blood pressure down 2–5 mmHg at four weeks, not sooner. This is the replicable finding Morand 2011. The window is the prediction: the acute trial with the same dose and confirmed metabolite exposure produced nothing at all Schar 2015, so anyone testing this over a weekend will correctly measure zero and incorrectly conclude the product is inert. Seven consecutive morning home-cuff readings averaged, before and after four weeks.

2. If the mechanism is leukocyte adhesion, the symptom that moves first is heaviness, not appearance. Predict evening leg heaviness and ankle circumference change while visible varicosities do not — adhesion-molecule biology acts on the microcirculation and on capillary leak, and it has no mechanism for shrinking a dilated superficial vein Allaert 2016Kakkos 2018. Measure ankle circumference with a tape at a marked height, same time each evening. A 1 cm reduction over four weeks is the scale of the published effect Kakkos 2018.

3. The prediction that cuts against the product. Hesperidin alone will underperform the diosmin–hesperidin fraction by a wide margin, because the fraction's evidence is 90% a different molecule Kakkos 2018. Predict that a plain hesperidin capsule at 500 mg/day produces no measurable change in ankle circumference at four weeks in someone with genuine venous insufficiency. If that is what you are buying it for, the honest version of this page says buy the studied fraction instead.

4. Response should be bimodal, and that is testable at home. Because absorption depends on a colonic bacterial rhamnosidase that varies several-fold between people Scalbert 2002, predict that a population splits into responders and non-responders rather than showing a smooth dose–response. The practical consequence: a single four-week trial in one person answers the question for that person and nobody else, and a non-response is more likely to be a microbiome than a dose.

What nobody has tested yet

Nobody has stratified a hesperidin trial by gut rhamnosidase activity. This is the obvious experiment and it has never been run. Measure urinary hesperetin conjugate excretion after a single 320 mg dose — a marker that is already validated by the acute metabolite study Schar 2015 — split the cohort into high and low converters, and then run the four-week endothelial protocol Morand 2011 within each stratum. If the blood-pressure effect lives entirely in the high converters, the product needs a companion test, and every trial averaging across both groups has been diluting its own effect.

Hesperidin has never been compared head-to-head with diosmin at equal milligrams. The entire clinical case rests on a fraction that is 90:10 Kakkos 2018. Nobody has run 450 mg diosmin alone against 450 mg hesperidin alone against the 90:10 mixture for twelve weeks with ankle circumference as the endpoint, which is the only way to find out whether the hesperidin fraction contributes anything at all.

Nobody has measured a venous-specific marker. Every venous trial in this field reads symptoms and a tape measure Kakkos 2018. Air plethysmography gives venous filling index and residual volume fraction; it is non-invasive, it takes twenty minutes, and it would say whether a flavonoid changes venous hemodynamics or only how the leg feels.

And the four-hour/four-week gap has never been explained. Same dose, same molecule, confirmed metabolite exposure, nothing acutely Schar 2015 and a real effect at four weeks Morand 2011. A time-course study with weekly measurement would locate the onset, and the shape of that curve would say whether the mechanism is transcriptional adaptation or something slower and structural. It is one extra visit per week and nobody has paid for it.

Hesperidin — its own safety story, not its category's

The interaction that actually matters is a transporter, not a P450. The commonly printed caution for citrus flavonoids is CYP3A4 inhibition, imported wholesale from grapefruit. Grapefruit's CYP3A4 effect belongs to its furanocoumarins, and hesperidin is not a furanocoumarin. The documented citrus interaction that hesperidin is implicated in runs through the uptake transporters instead — OATP1A2 and OATP2B1 on the enterocyte, which orange juice inhibits, reducing rather than increasing the absorption of their substrates. Fexofenadine is the textbook case; aliskiren and atenolol behave similarly. The practical rule is the opposite of the grapefruit rule: the risk is underdosing a drug, not overdosing it, and the fix is separating the flavonoid from the medicine by several hours.

Blood pressure, additive and small but real. The four-week trial lowered diastolic pressure at 320 mg/day in healthy men Morand 2011. On an antihypertensive that is additive, and the group most likely to notice is older readers on a diuretic or an alpha-blocker who stand up quickly. Two to five millimetres is not dangerous on its own; it is dangerous stacked on three other things each doing the same.

The venous-disease caution that is a diagnosis rather than an interaction. Unilateral leg swelling, calf pain and warmth is deep vein thrombosis until a scan says otherwise, and a flavonoid that reduces the symptoms of venous congestion Kakkos 2018 can blunt exactly the signal that should be sending you for that scan. The rule is simple: bilateral, gradual, worse in the evening, better overnight is venous insufficiency. One leg, over days, is not, and no supplement belongs in that conversation.

Pregnancy, and why the answer is genuinely unknown. Hemorrhoids and leg edema in the third trimester are the two commonest reasons anybody reaches for this class, and pregnant women are systematically excluded from the trials that generated the evidence Kakkos 2018. That is an absence of data, not a reassurance and not a finding of harm, and it is worth saying plainly because the population most likely to want this is the population least studied.

Gastrointestinal upset and headache are the usual reports and are dose-related. Mild antiplatelet activity is plausible for the class and worth flagging alongside anticoagulants, though it is far weaker here than for the tannin-heavy botanicals.

Sources read for this page

• Morand C, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers.. American Journal of Clinical Nutrition 2011 · PMID 21068346
• Schar MY, et al. Orange juice-derived flavanone and phenolic metabolites do not acutely affect cardiovascular risk biomarkers: a randomized, placebo-controlled, crossover trial in men at moderate risk of cardiovascular disease.. American Journal of Clinical Nutrition 2015 · PMID 25788001
• Kakkos SK, et al. Efficacy of micronized purified flavonoid fraction (Daflon) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.. International Angiology 2018 · PMID 29385792
• Allaert FA. Combination of Ruscus aculeatus extract, hesperidin methyl chalcone and ascorbic acid: a comprehensive review of their pharmacological and clinical effects and of the pathophysiology of chronic venous disease.. International Angiology 2016 · PMID 26928296
• Manach C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies.. American Journal of Clinical Nutrition 2005 · PMID 15640486
• Scalbert A, et al. Absorption and metabolism of polyphenols in the gut and impact on health.. Biomedicine & Pharmacotherapy 2002 · PMID 12224598

How you would know if it worked

Hesperidin — safety & side effects

Bloodwork to run alongside Hesperidin

Baseline first, then again at 8–12 weeks.

The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.

Check results you already have → · All 103 markers A–Z

Hesperidin — frequently asked questions

What Hesperidin is used for

Hesperidin appears under 1 goal in the goal router.

Related Cardiovascular supplements

← Browse the full Supplement Vault

↑ Back to on this page